semaglutide
Conquer GI Bumps With Semaglutide’s OASIS Data
70% of patients in the OASIS trial experienced mild GI symptoms in the first month, so managing those bumps is essential for staying on track with weight loss. Early mitigation strategies can preserve adherence and let you reap the full 12% average weight loss shown in Phase 3 studies. Medical